274 related articles for article (PubMed ID: 18445856)
1. KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature.
de Reyniès A; Boige V; Milano G; Faivre J; Laurent-Puig P
J Clin Oncol; 2008 May; 26(13):2228-30; author reply 2230-1. PubMed ID: 18445856
[No Abstract] [Full Text] [Related]
2. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
3. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
Nozawa K; Watanabe T
Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
[TBL] [Abstract][Full Text] [Related]
4. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
Cremolini C; Loupakis F; Ruzzo A; Perrone G; Rulli E; Vincenzi B; Tonini G; Graziano F; Muda AO; Falcone A
J Clin Oncol; 2010 Apr; 28(11):e173-4; author reply e175-6. PubMed ID: 20177018
[No Abstract] [Full Text] [Related]
5. [Biology applied to cancer treatments: the example of colorectal cancer].
Lièvre A; Laurent-Puig P
Rev Prat; 2010 Oct; 60(8):1100-2. PubMed ID: 21197742
[No Abstract] [Full Text] [Related]
6. MicroRNA profiling predicts survival in anti-EGFR treated chemorefractory metastatic colorectal cancer patients with wild-type KRAS and BRAF.
Mosakhani N; Lahti L; Borze I; Karjalainen-Lindsberg ML; Sundström J; Ristamäki R; Osterlund P; Knuutila S; Sarhadi VK
Cancer Genet; 2012 Nov; 205(11):545-51. PubMed ID: 23098991
[TBL] [Abstract][Full Text] [Related]
7. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
Kim R; Kubal T
Clin Colorectal Cancer; 2012 Jun; 11(2):85-7. PubMed ID: 22169039
[No Abstract] [Full Text] [Related]
8. KRAS status predicts response to cetuximab for metastatic colorectal cancer.
McBride D
ONS Connect; 2008 Aug; 23(8):25. PubMed ID: 18767573
[No Abstract] [Full Text] [Related]
9. Should KRAS mutations be considered an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab?
Garassino MC; Farina G; Rossi A; Martelli O; Torri V
J Clin Oncol; 2008 May; 26(15):2600; author reply 2601-2. PubMed ID: 18487581
[No Abstract] [Full Text] [Related]
10. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies.
Wong R; Cunningham D
J Clin Oncol; 2008 Dec; 26(35):5668-70. PubMed ID: 19001346
[No Abstract] [Full Text] [Related]
11. Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.
Katsios C; Ziogas DE; Roukos DH
Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):525-9. PubMed ID: 20932136
[No Abstract] [Full Text] [Related]
12. Cetuximab in metastatic colorectal cancer.
Broadbridge VT; Karapetis CS; Price TJ
Expert Rev Anticancer Ther; 2012 May; 12(5):555-65. PubMed ID: 22594891
[TBL] [Abstract][Full Text] [Related]
13. Interferon/STAT1 and neuregulin signaling pathways are exploratory biomarkers of cetuximab (Erbitux®) efficacy in KRAS wild-type squamous carcinomas: a pathway-based analysis of whole human-genome microarray data from cetuximab-adapted tumor cell-line models.
Oliveras-Ferraros C; Vazquez-Martin A; Queralt B; Adrados M; Ortiz R; Cufí S; Hernández-Yagüe X; Guardeño R; Báez L; Martin-Castillo B; Pérez-Martínez MC; Lopez-Bonet E; De Llorens R; Bernadó L; Brunet J; Menendez JA
Int J Oncol; 2011 Dec; 39(6):1455-79. PubMed ID: 21833472
[TBL] [Abstract][Full Text] [Related]
14. EGFR antibodies in colorectal cancer: where do they belong?
Grothey A
J Clin Oncol; 2010 Nov; 28(31):4668-70. PubMed ID: 20921457
[No Abstract] [Full Text] [Related]
15. Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer.
Tsoukalas N; Tzovaras AA; Tolia M; Kostakis ID; Papakostidi A; Pistamaltzian N; Ardavanis A
J BUON; 2012; 17(1):73-8. PubMed ID: 22517696
[TBL] [Abstract][Full Text] [Related]
16. KRAS mutation in metastatic colorectal cancer and its impact on the use of EGFR inhibitors.
Lenz HJ; Chu E; Grothey A
Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-13, 14-6. PubMed ID: 19378369
[TBL] [Abstract][Full Text] [Related]
17. Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer.
Lieberman R
Am J Ther; 2009; 16(6):477-9. PubMed ID: 19829092
[No Abstract] [Full Text] [Related]
18. KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.
Baynes RD; Gansert J
Am J Ther; 2009; 16(6):554-61. PubMed ID: 19352138
[TBL] [Abstract][Full Text] [Related]
19. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.
Tian S; Simon I; Moreno V; Roepman P; Tabernero J; Snel M; van't Veer L; Salazar R; Bernards R; Capella G
Gut; 2013 Apr; 62(4):540-9. PubMed ID: 22798500
[TBL] [Abstract][Full Text] [Related]
20. Hurdles and complexities of codon 13 KRAS mutations.
Morelli MP; Kopetz S
J Clin Oncol; 2012 Oct; 30(29):3565-7. PubMed ID: 22927534
[No Abstract] [Full Text] [Related]
[Next] [New Search]